Related Experiment Videos
[Therapeutic experiences using the new podophyllotoxin derivative VP 16-213 in malignant human tumors]
Abstract:
The new semisynthetic epipodophyllotoxin VP 16-213 has been tested for antitumor activity and toxicity in a non-randomized phase II trial. The study included 33 patients with solid tumors and acute leukemias. The drug was given in 5-day courses every 3 weeks, parenterally for the first 2 courses and thereafter orally. Subjectively VP 16-213 was well tolerated in both i.v. and oral administration, but almost universally induced leukothrombopenia and hair loss. The best results were achieved in 12 patients with oat cell carcinoma of the lung (4 good and 4 less good responses). Remissions of lesser quality were also observed in anaplastic lung cancer, ovarian carcinoma and acute myelomonocytic leukemia. VP 16-213 possesses proven, clinically valuable cytostatic activity against various human neoplasms. Complementary studies to establish its optimum dosage and administration, and its place in combination chemotherapy, are in progress.
Insights
The new epipodophyllotoxin VP 16-213 shows significant antitumor activity in patients with solid tumors and acute leukemias. Further studies are ongoing to optimize its dosage and use in combination chemotherapy.
Area of Science:
- Oncology
- Pharmacology
Context:
- A non-randomized phase II trial evaluated the antitumor activity and toxicity of VP 16-213.
- The study involved 33 patients diagnosed with solid tumors and acute leukemias.
Purpose:
- To assess the efficacy and safety of the semisynthetic epipodophyllotoxin VP 16-213.
- To determine the clinical value of VP 16-213 in treating various human neoplasms.
Summary:
- VP 16-213 was administered in 5-day courses, initially parenterally then orally, and was generally well-tolerated.
- Common side effects included leukothrombopenia and alopecia; however, significant responses were observed in oat cell lung carcinoma, anaplastic lung cancer, ovarian carcinoma, and acute myelomonocytic leukemia.
- The drug demonstrated clinically valuable cytostatic activity against multiple human neoplasms.
Impact:
- VP 16-213 exhibits proven cytostatic activity, offering a potentially valuable treatment option for various cancers.
- Ongoing research aims to establish optimal dosing, administration, and combination chemotherapy protocols for VP 16-213.